| Name | Tirofiban |
| Description | Tirofiban (L700462) (MK-383) is a selective palate GPIIb/IIIa antagonist which inhibits platelet aggregation with IC50 of 9 nM. |
| In vitro | Tirofiban (MK-383, Aggrastat) is a nonpeptide derivative of tyrosine that selectively inhibits the GP-IIb/IIIa receptor, with minimal effects on the ɑvβ3 vitronectin receptor. [1][2] It inhibits platelet aggregation of gel-filtered platelets induced by 10 μM ADP with IC50 of 9 nM, but the IC50 for inhibition of human umbilical vein adhesion to vitronectin, which depends on ɑvβ3 vitronectin receptors, is 62 μMol/L. [3] |
| In vivo | Tirofiban (10 to 500 mg/kg or 360-min continuous i.v. infusions of 1 to 10 micrograms/kg/min) inhibits platelet aggregation responses to ADP and collagen in canine models. [4] When administered to humans at 0.15μg/kg/min for 4 h, Tirofiban produced a 2.5-fold increase in bleeding time and 97% inhibition of ADP-induced platelet aggregation. [5][6] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : < 1 mg/mL (insoluble or slightly soluble)
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
H2O : < 1 mg/mL (insoluble or slightly soluble)
1M HCL : 54 mg/mL (122.56 mM)
|
| Keywords | VEGF | Tirofiban | MK-383 | MK 383 | L-700462 | L 700462 | Integrin | Inhibitor | inhibit | HUVEC | HAEC | GPIIb/IIIa | antithrombotic | AMI | ACSs |
| Inhibitors Related | K34c hydrochloride | Cucurbitacin B | Tirofiban hydrochloride monohydrate | (R)-Leucic acid | Lifitegrast | Cyclo(-RGDfK) | ADH-503 | Elsibucol | CLT-28643 | Bestatin hydrochloride | Gantofiban | 2-hydroxy Flutamide |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Drug-induced Liver Injury (DILI) Compound Library | Toxic Compound Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | Anti-Cardiovascular Disease Compound Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | Human Metabolite Library |
United States
